REGEN BIOMEDICAL
High quality functional micro tissues
OUR BUSINESS
ReGEN Biomedical focusses on growing large amounts of robust and reproducible small pieces of tissue (micro tissues) for toxicity- & pharma-screening. Functional micro-tissues present the next step in mimicking patient organs and represent the future of personalized medicine.
​
We are building expertise on how to assemble the micro-tissues into functional pieces of human organs, so-called macro-tissues. The micro tissues also serve as building blocks for RM-therapies and will be assembled into functional macro tissues.
It is the aim to fully automate all production platforms and equip these with advanced appropriate offline and inline quality control systems. The platform technology also enables this initiative to realize sales and licensing for specific drug screening opportunities and ex vivo disease models. The large-scale production is one of the foundations of the development of a new (manufacturing) industry around affordable Regenerative Medicine solutions.
"We are very proud of this investment. It will allow us to build an infrastructure for the development of regenerative therapies that can really help patients in the future. At the moment, healthcare focuses mainly on controlling symptoms, but we are committed to curing diseases such as type 1 diabetes, kidney failure, osteoarthritis and heart failure. This award brings that end goal a big step closer."
Prof. Dr. Marianne van der Steen, CEO
WHY NOW?
Regenerative Medicine (RM) aims to repair or restore the function of tissues and organs that can prevent or cure chronic diseases. The social and economic potential is enormous: in terms of years of life gained, lower healthcare costs, emergence of new companies and a new RM industry serving a global healthcare market.
One of the major challenges in availability and affordability for patients is the industrialization of implant production. This is complex, has to meet high standards and is labor-intensive and hardly automated at all.
​
Via RegMed XB the Groeifonds (Growth Fund) aids to to build a regenerative medicine pilot factory. RegMed XB is a partnership of research institutions, governments, provinces, health funds and businesses in the Netherlands and Flanders to develop therapies for chronic diseases, based on stem cells, mini-organs, tissues and smart (bio)materials. The RM factory consists of four pilot plants - four state-of-the-art facilities in Eindhoven, Leiden, Maastricht and Utrecht that co-develop the main production platforms of the pilot factory
PARTNERS
